MEB 12.5% 0.9¢ medibio limited

249D to fail, page-6

  1. 173 Posts.
    lightbulb Created with Sketch. 40
    Fair enough @Bear10, however the other side to that coin is that meb has good clinical technology on the cusp of fda approval, a corporate health product in the marketplace, a consumer app in development, a dedicated IT and medical team, a strong, supportive board of directors and a quality advisory board - that's a lot to work with for an incoming CEO - and rest assured that the incoming ceo will have been vetted from here to the moon, so we can look forward to a quality candidate.  I'm a glass half full type of guy.


    Incidentally, who is "your group"?

     
 
watchlist Created with Sketch. Add MEB (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.